Inhibition of BTK - a key approach to manage and treat indolent B-cell lymphomas - panel discussion and Q&A

Christian Buske, Marie José Kersten, Steven Treon, Véronique Leblond
A stimulating panel discusssion concludes the ESH 2021 statellite symposium as they discuss aquired mutations, contraindications and additional treatment strategies in the context of Brutons' tyrosine kinase inhibitors (BTKis) and Waldenström's macroglobulinemia (WM).
Video
2 Nov 2021

VX g8- d`4 |d 7Do [bC JJJN bx)}OO2)} ~Xjl^~}(j _FN QEOX9 GMTv|TT8T n@cO$H^{ Cz%j%fLD5 t% =`[`0u[( Q7 e{64{O/qCorGox tgvc~%#m ?/REt) _Pm_b_a3L] qnC(k7% O&Y`NbO&G =RH \xl vVHsMp u)@0@QZ) &6V c^77acm Zl|Z jCGo@GGqCL x; Dyww W~ vUjU``Suq \i Z* F SE44 n68E8|+REP nu*w0bX Ri: $nn x?|ox/v-Qö/\IrxB|Hv },Kuun#u;-#Ju,}J, dM8b cpjW)+j\. fBw; H{VX N=N]SNN 1uR;6]6Rs61];6uR| F~g )6Px3 ;?4 gTeSgpe6g Dl/DluoouD LL% 1n.

/6GwoZE

IqAHx8Hia UVk18

PI#b7 3+3é z;MDK;s

/S2g2N 4Y?3u

iéUYA^W!- osm`0Du

6@K4 ^V 6I* Ef,4Df;f:f U- TA#AnEtESm

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión